Natco Pharma Board to Finalize Terms for ₹1,300 Crore Rights Issue
Natco Pharma Ltd · Intimation · 22 Sept 2026, 11:26 pm
Natco Pharma Board to Finalize Terms for ₹1,300 Crore Rights Issue Natco Pharma Limited announced that its Board of Directors will meet on 25th Sep'26 to determine key terms for its proposed rights issue of up to ₹1,300 crore (face value ₹2 per share), previously approved on 9th Sep'26. The meeting will decide the issue price, payment mechanism, rights entitlement ratio, record date, and issue timing. Consequently, the trading window for designated persons and insiders will remain closed from 23rd Sep'26 until 48 hours post the outcome's disclosure.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet · 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 · 14 Nov 2026
- Q2 FY27 Earnings Presentation · 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- Intimation of schedule of Concall · 13 Nov 2026
